VAL66MET (SNP rs6265) GENOTYPE SPECIFIC DOSING REGIMENS AND METHODS FOR THE TREATMENT OF DEPRESSION

摘要

The present invention is directed to methods and dosing regimens for the treatment of depression (preferably, treatment resistant depression), for the treatment of depression in a suicidal patient, and/or for the treatment and/or prevention of suicidality (e.g. suicidal ideations) comprising genotyping a patient to determine their Val66Met rs6265 polymorphism in BDNF and administering a ketamine, preferably esketamine, preferably intranasal esketamine, according to a dosing regimen matched to the patient's genotype.

主权项

1. A method for the treatment of depression, for the treatment of depression in a suicidal patient, for the treatment of suicidality or for the prevention of suicidality, comprising
Step A: genetically testing a patient suffering from depression to determine their Val66Met rs6265 polymorphism in the BDNF gene; and Step B: administering esketamine according to an induction phase regimen;
wherein the induction phase comprises a treatment period of between 2 and 8 weeks;wherein the esketamine is administered at a dosing frequency of one to five times per week;wherein, if the patient is a Val/Val homozygote, then the esketamine is administered at a dosage in an amount in the range of from about 28 mg to about 56 mg;wherein, if the patient is a Val/Met heterozygote or a Met/Met homozygote, then the esketamine is administered at a dosage in an amount in the range of from about 56 mg to about 84 mg;and wherein, during the induction phase, the dosage amount or the dosing frequency for the patient who is a Val/Val homozygote and the dosage amount or the dosing frequency for the patient who is a Val/Met heterozygote or Met/Met homozygote is different.